Copyright: ©Author(s) 2026.
World J Gastroenterol. Jan 14, 2027; 33(2): 123795
Published online Jan 14, 2027. doi: 10.3748/wjg.123795
Published online Jan 14, 2027. doi: 10.3748/wjg.123795
Figure 6 Melatonin suppressed VEGF signaling and interactions between VEGFR-2 and POMK.
A: Western blotting of VEGFR-2 signaling in human umbilical vein endothelial cells (HUVECs) treated with VEGFA, melatonin, or AZD2171; B: Quantitative analysis of the activation of VEGFR-2 signaling; C: Immunoprecipitation (IP) blotting of VEGFR-2 in HUVECs and subjected of IP-mass spectrometry; D: PPI network of enriched proteins by IP-mass spectrometry; E: IP blotting of DOCK5 by VEGFR-2 in HUVECs; F: IP blotting of DSG1 by VEGFR-2 in HUVECs; G: IP blotting of POMK by VEGFR-2 in HUVECs; H: Quantitative analysis of IP blotting. aP < 0.05. bP < 0.01. MLT: Melatonin.
- Citation: Wu GB, Luo GQ, Chen M, Cai KW, You XT, Han F, Zhang NZ, Luo M, Li Q, Huo HZ, Fan Q. Melatonin attenuates splanchnic hyperdynamic circulation in cirrhotic portal hypertension by disrupting POMK-VEGFR2 interaction. World J Gastroenterol 2027; 33(2): 123795
- URL: https://www.wjgnet.com/1007-9327/full/v33/i2/123795.htm
- DOI: https://dx.doi.org/10.3748/wjg.123795